ARECOR AND TRx BIOSCIENCES ESTABLISH RESEARCH COLLABORATION TO DEVELOP ORAL GLP-1 WITH ENHANCED BIOAVAILABILITY - Companies to combine proprietary technologies to formulate an oral semaglutide (GLP-1 receptor agonist) product with enhanced bioavailability - Collaboration focused on overcoming the challenges of oral peptide delivery using a novel lipid technology to provide a more convenient treatment option for patients with diabetes and obesity - Potential to expand collaboration across multiple oral peptide products and combination therapies in growing global market Cambridge, UK, 12 March…

Biocair is calling for greater investment in women in STEM (science, technology, engineering and mathematics). The company believes these male-dominated sectors could benefit hugely from greater diversity. Despite the rapid growth of the sector, women currently make up only 26% of the STEM workforce in the UK and just 28% in the USA. To combat this disparity, Biocair echoes the United Nation’s theme of International Women’s Day 2024: “Invest in women: Accelerate progress”. As the global specialist in temperature-controlled logistics for life sciences, Biocair understands the importance of…

Read eNews March here Exciting Developments for our Network, featuring: ✅ Welcome from Tony Jones, CEO, One Nucleus ✅ Get your Boots on for Boston 2024! ✅ Who will be Crowned Best in Class?  ✅ And the Voting isn’t Over – Now it’s Your Turn? ✅ Save with us for these Two Global Events  

AMSBIO has expanded its range of products and services dedicated to assisting scientists diversify their preclinical models effectively to help bridge the gender discrepancy gap in many areas of research. Until 1993, most clinical trial participants were men of European descent, leading to a lack of data on the safety and efficacy of treatments for women and diverse populations. Although attitudes in clinical trials are changing, inclusivity in preclinical research is still often overlooked, leading to critical gaps in our understanding of how drugs and treatments affect different populations…

Time-poor start-up founders need life science clusters to thrive Mairi Dillion at Kadans Trying to survive as a start-up can feel like an uphill battle. Finding investment, building partnerships, and reaching new audiences can be tricky on tight budgets and deadlines. And in the life sciences sector, this can prove even more challenging. There are over 60,000 SMEs in human, health, and social work competing for survival, with a worrying half of new businesses failing within the first three years of operation. While the picture may seem bleak, the pharmaceutical sector is a pillar of the UK…

 Read the newsletter here.

Neobe Therapeutics, a pioneering synthetic biology startup at the forefront of immuno-oncology innovation, is thrilled to announce the successful closure of a $2.34m financing round. This significant financial milestone was achieved with the support of new investors Pioneer Group and 2048 Ventures, alongside existing backers Deep Science Ventures*, Cancer Research Horizons*, and Discovery Park Ventures. Additionally, the round received a non-dilutive grant award from UKRI’s Innovate UK Future Economy Investor Partnership Programme. Neobe has built a synthetic biology platform to engineer safe…

Discovery Park to host two events to celebrate women in business and tackle challenges in women’s health. Discovery Park, Kent’s thriving life science community, is marking International Women’s Day by supporting women in business and tackling gender bias in healthcare. With female founded start-ups still struggling to access funding and a lack of women investors, there remains much to do to create an equitable environment for women in business. The femtech industry is a clear example of this gender bias, with male femtech founders consistently raising more capital despite over 70% of…

In a recent blog post – AMSBIO describe how life science research groups are using their BioPORTER®, Detachin™, and SoluLyse™ reagents to make groundbreaking advances in Parkinson’s research, hypersomnia studies and eco-friendly microbial ester production. These novel reagents empower research by enhancing the efficiency, accuracy, and reproducibility of scientific investigations. A collaborative effort led by Dr. Wenjing Wang at the University of Michigan and Dr. Xiaobo Mao of Johns Hopkins University School of Medicine has made exciting advances in the development of potential therapeutics…

Cambridge, UK 23 February 2024 We are pleased to announced the shortlist for the One Nucleus Awards 2024. The One Nucleus Award categories are structured to reflect that breadth of R&D, investment, service provision and enabling support across the stakeholders. “Performance of the Year” being recognised in each category.  The awards criteria recognise success between 1 December 2022 – 30 November 2023. Best Performing Facilities Provider of the Year: Babraham Research Campus Bruntwood SciTech Stevenage Bioscience Catalyst   Best Performing Investor of the Year: Cambridge…